Antimyelin antibodies as predictors of disability after clinically isolated syndrome

Findling, Oliver; Durot, Isabelle; Weck, Anja; Jung, Simon; Kamm, Christian P.; Greeve, Isabell; Mattle, Heinrich P.; Sellner, Johann (2014). Antimyelin antibodies as predictors of disability after clinically isolated syndrome. International journal of neuroscience, 124(8), pp. 567-572. Informa Healthcare 10.3109/00207454.2013.869221

Full text not available from this repository.

There is controversy whether determination of antibodies against myelin, myelin oligodendrocyte glycoprotein, and myelin basic protein in serum from patients with a first episode suggestive of multiple sclerosis is of prognostic value. We evaluated whether detection of antimyelin antibodies in serum indicates a worse course with earlier time to a second relapse and increased progression of disability. We conducted a prospective study at the Department of Neurology, Inselspital Bern, Switzerland from 2004 to 2008 in patients presenting with a clinically isolated syndrome (CIS) and a follow-up of at least 4 months. Antimyelin antibodies were assessed by Western blot. Results were correlated with clinical course and sex. Among 93 consecutive patients with a CIS, 74 (80%) were positive for either one or both antimyelin antibodies. A relapse occurred in 49 (53%) and the median EDSS was 2 (range 1-3.5) after a mean observation period of 20 months. Presence of antimyelin antibodies at CIS neither increased the risk for a second relapse nor for progression of disability. Stratification for gender did not reveal differences for any of the clinical surrogates. The sole determination of antimyelin antibodies in serum is of limited prognostic value for the identification of patients with different short-term course.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
UniBE Contributor:	Findling, Oliver, Weck, Anja, Jung, Simon, Kamm, Christian Philipp, Greeve, Isabell, Mattle, Heinrich, Sellner, Johann
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0020-7454
Publisher:	Informa Healthcare
Language:	English
Submitter:	Gabriela Horber
Date Deposited:	24 Apr 2014 10:12
Last Modified:	05 Dec 2022 14:29
Publisher DOI:	10.3109/00207454.2013.869221
PubMed ID:	24274327
Uncontrolled Keywords:	autoimmunity, biomarker, multiple sclerosis, prognosis
URI:	https://boris.unibe.ch/id/eprint/43715